206 related articles for article (PubMed ID: 11706397)
1. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
Albanell J; Rojo F; Baselga J
Semin Oncol; 2001 Oct; 28(5 Suppl 16):56-66. PubMed ID: 11706397
[TBL] [Abstract][Full Text] [Related]
2. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Albanell J; Rojo F; Averbuch S; Feyereislova A; Mascaro JM; Herbst R; LoRusso P; Rischin D; Sauleda S; Gee J; Nicholson RI; Baselga J
J Clin Oncol; 2002 Jan; 20(1):110-24. PubMed ID: 11773160
[TBL] [Abstract][Full Text] [Related]
6. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
Magné N; Fischel JL; Dubreuil A; Formento P; Poupon MF; Laurent-Puig P; Milano G
Br J Cancer; 2002 May; 86(9):1518-23. PubMed ID: 11986789
[TBL] [Abstract][Full Text] [Related]
7. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
8. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
9. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
[TBL] [Abstract][Full Text] [Related]
10. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
[TBL] [Abstract][Full Text] [Related]
11. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
[TBL] [Abstract][Full Text] [Related]
12. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Herbst RS
Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
14. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
Sumitomo M; Asano T; Asakuma J; Asano T; Horiguchi A; Hayakawa M
Clin Cancer Res; 2004 Jan; 10(2):794-801. PubMed ID: 14760103
[TBL] [Abstract][Full Text] [Related]
15. The role of EGFR-directed therapy in the treatment of breast cancer.
Morris C
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S51-5; discussion S57-9. PubMed ID: 12353824
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
17. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
Solomon B; Hagekyriakou J; Trivett MK; Stacker SA; McArthur GA; Cullinane C
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):713-23. PubMed ID: 12573759
[TBL] [Abstract][Full Text] [Related]
18. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
Daneshmand M; Parolin DA; Hirte HW; Major P; Goss G; Stewart D; Batist G; Miller WH; Matthews S; Seymour L; Lorimer IA
Clin Cancer Res; 2003 Jul; 9(7):2457-64. PubMed ID: 12855618
[TBL] [Abstract][Full Text] [Related]
19. Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Hidalgo M; Amador ML; Jimeno A; Mezzadra H; Patel P; Chan A; Nielsen ME; Maitra A; Altiok S
Mol Cancer Ther; 2006 Jul; 5(7):1895-903. PubMed ID: 16891476
[TBL] [Abstract][Full Text] [Related]
20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]